Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of HMPL-523 Acetate Formulations
NCT07331194Phase 1Completed
- Sponsor
- HUTCHMED
- Start
- Oct 2025
- Primary completion
- Nov 2025
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sovleplenib in immune thrombocytopenia (ITP) (2 arms), sponsored by HUTCHMED. Primary endpoints: Pharmacokinetic parameters (Cmax, AUC) at 2 months and Bioequivalence of two drug formulations at 2 months. Started Oct 2025; status: completed.
02
Drugs
sovleplenib
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT07331194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07331194.